Related Experiment Video
Updated: Nov 2, 2025
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort
Jennifer Ezirike Ladipo1,2,3, Zhaoping He4, Kudakwashe Chikwava5
1Division of Pediatric Gastroenterology.
Objectives:
This study aimed to determine whether mRNA expression of oncostatin-M (OSM) and its receptor (OSMR) in initial, pre-treatment intestinal biopsies is predictive of response to tumor necrosis factor antagonists (anti-TNF) in a pediatric inflammatory bowel disease (IBD) cohort. Secondary outcomes correlated OSM and OSMR expression with demographic variables; IBD type, extent, phenotype, and severity; laboratory values; and endoscopic findings.
Methods:
A retrospective chart review was conducted on 98 pediatric patients. Patients' clinical courses were stratified as follows: failed anti-TNF (n = 14), quiescent on anti-TNF (n = 36), anti-TNF naïve (n = 19), and age-matched non-IBD controls (n = 29). The mRNA from each patient's pre-treatment ileal or colonic biopsy was isolated, and expression of OSM and OSMR was analyzed.
Results:
There was no difference in OSM or OSMR expression among the three IBD groups; however, expression was significantly higher in patients with IBD than non-IBD controls (P < 0.001). OSM and OSMR were more highly expressed in patients with ulcerative colitis (UC) with a Mayo score of 3 (P = 0.0092 and P = 0.0313, respectively). High OSM expression correlated with severe disease activity indices at diagnosis (P = 0.002), anemia at diagnosis (P = 0.0236), and need for immunomodulators (P = 0.0193) and steroids (P = 0.0273) during patients' clinical courses.
Conclusions:
OSM and OSMR expression were not predictive of response to anti-TNF in our pediatric cohort. OSM expression did correlate with IBD compared with healthy controls as well as with several clinical indicators of severe IBD.
Insights
Oncostatin-M (OSM) and its receptor (OSMR) mRNA expression in pediatric inflammatory bowel disease (IBD) patients did not predict response to anti-tumor necrosis factor (anti-TNF) therapy. However, higher OSM expression correlated with more severe IBD.
Area of Science:
- Gastroenterology
- Immunology
- Molecular Biology
Background:
- Pediatric inflammatory bowel disease (IBD) management often involves anti-tumor necrosis factor (anti-TNF) therapies.
- Predicting treatment response in pediatric IBD is crucial for optimizing patient outcomes.
- Oncostatin-M (OSM) and its receptor (OSMR) are cytokines implicated in inflammatory processes.
Purpose of the Study:
- To investigate whether pre-treatment mRNA expression of OSM and OSMR in intestinal biopsies can predict response to anti-TNF therapy in pediatric IBD patients.
- To explore correlations between OSM/OSMR expression and various clinical and laboratory parameters in pediatric IBD.
Main Methods:
- Retrospective chart review of 98 pediatric patients with IBD and age-matched non-IBD controls.
- Analysis of mRNA expression of OSM and OSMR from pre-treatment ileal or colonic biopsies.
- Stratification of IBD patients into anti-TNF responders, non-responders, and anti-TNF naive groups.
Main Results:
- OSM and OSMR expression were significantly higher in pediatric IBD patients compared to non-IBD controls.
- Elevated OSM and OSMR expression was observed in ulcerative colitis patients with a Mayo score of 3.
- High OSM expression correlated with severe disease activity, anemia at diagnosis, and the need for immunomodulators and steroids.
Conclusions:
- OSM and OSMR mRNA expression in initial biopsies are not predictive of anti-TNF treatment response in pediatric IBD.
- OSM expression is associated with the presence and severity of IBD, as well as indicators of disease activity.
More Related Videos
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Drugs for Treatment of Ulcerative Colitis in IBD